Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics, Inc. of shares of its common stock for up to a maximum offering price of $100 million.
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. Its lead product candidate is a novel central nervous system penetrant aldose reductase inhibitor being developed for the treatment of galactosemia, a rare pediatric metabolic disease.
The Davis Polk capital markets team included partner Richard D. Truesdell Jr., counsel Alain Kuyumjian and associates Amanda Rae Schwarzenbart and Chloe Wang. Partner Michael Mollerus provided tax advice. The intellectual property and technology transactions team included partner David R. Bauer and associate Yifu Chen. Counsel Loyti Cheng and associate Cristina Harshman provided environmental advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.